• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of peptide vaccine therapy targeting oral cancer stem cells with comprehensive HLA ligandome analysis

Research Project

Project/Area Number 17K17282
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Surgical dentistry
Research InstitutionUniversity of the Ryukyus (2019)
Sapporo Medical University (2017-2018)

Principal Investigator

Miyamoto Sho  琉球大学, 医学部附属病院, 助教 (80749565)

Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywordsペプチドワクチン / がん幹細胞 / 腫瘍免疫 / がん免疫 / がん解細胞 / 免疫療法 / 再発予防 / ナチュラルペプチド / 口腔がん
Outline of Final Research Achievements

Cancer stem cells (CSCs) explain the resistance to chemo/radiotherapies and cancer-initiating abilities of low numbers of cells in vivo. In order to target them through CTL recognition, we first isolated the CSC population from the cancer line, SW480, with an established side-population method. And screened the natural HLA-A24 ligandome by LC-MS/MS, resulting in identification of a CSC-specific natural antigenic peptide, IV9.
The IV9 specific CTLs were induced from PBMC stimulated by IV9 peptide. IV9 specific CTL recognized CSCs but not non-CSCs. And in immunodeficient mice, intravenous injection of the IV9 specific CTL successfully prevented growth of the original SW480 cells. As the cancer cells implanted in these mice contained very few CSCs, the elimination of a CSC subset could be the condition necessary and sufficient to control tumor formation in vivo. These results suggest that CTL-based immunotherapies against colorectal CSCs might be useful for preventing relapses.

Academic Significance and Societal Importance of the Research Achievements

がん解細胞を標的とした、新規ペプチドワクチンの開発に成功した。また本研究を通し、がん幹細胞成分を排除することが、腫瘍形成を制御するのに必要かつ十分な条件であることを証明している。このことは、CTL免疫療法の治療・予防戦略において、がん幹細胞を標的とすることの有効性を示唆する結果となっており、今後のあらゆるがんの再発予防法の開発・研究を行うにあたり、指標となる重要な結果が得られた。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (8 results)

All 2019 2018

All Journal Article (3 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 3 results,  Open Access: 1 results) Presentation (5 results) (of which Int'l Joint Research: 2 results,  Invited: 1 results)

  • [Journal Article] Upstream Position of Proline Defines Peptide-HLA Class I Repertoire Formation and CD8(+) T Cell Responses.2019

    • Author(s)
      Hongo A, Kanaseki T, Tokita S, Kochin V, Miyamoto S, Hashino Y, Codd A, Kawai N, Nakatsugawa M, Hirohashi Y, Sato N, Torigoe T
    • Journal Title

      The Journal of Immunology

      Volume: 10 Pages: 2849-2855

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] がん幹細胞特異的抗原ASB4を利用したがん免疫治療2018

    • Author(s)
      金関貴幸,宮本昇,鳥越俊彦
    • Journal Title

      臨床免疫・アレルギー科

      Volume: 69 Pages: 499-504

    • NAID

      40021567695

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer2018

    • Author(s)
      Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, Takaya A, Hirohashi Y, Tsukahara T, Terui T, Ishitani K, Hata F, Takemasa I, Miyazaki A, Hiratsuka H, Sato N, Torigoe T.
    • Journal Title

      Cancer Immunology Research

      Volume: -

    • Related Report
      2017 Research-status Report
    • Peer Reviewed
  • [Presentation] HLAリガンドーム解析による新規がん幹細胞抗原ペプチドの同定と腫瘍ワクチンへの応用2019

    • Author(s)
      宮本昇、宮﨑晃亘、仲宗根敏行、西原一秀、荻和弘、出張裕也
    • Organizer
      第64回公益社団法人 日本口腔外科学会総会・学術大会
    • Related Report
      2019 Annual Research Report
  • [Presentation] A cancer-stem cell specific antigen, ASB4, as a unique target for effective CTL immunotherapy of colorectal cancer2019

    • Author(s)
      宮本昇
    • Organizer
      平成31年度札幌医科大学大学院医学研究科前期研修プログラム(基礎講義)
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] Development of peptide vaccine therapy targeting colon cancer stem cells with HLA ligandome analysis2018

    • Author(s)
      Sho Miyamoto, Takayuki Kanaseki, Akihiro Miyazaki, Toshihiko Torigoe
    • Organizer
      PEGS Europe Protein & Antibody Engineering Summit 2018
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] A cancer-stem cell specific antigen, ASB4, as a unique target for effective CTL immunotherapy of colorectal cancer2018

    • Author(s)
      Sho Miyamoto, Takayuki Kanaseki, Akihiro Miyazaki, Hiroyoshi Hiratsuka, Toshihiko Torigoe
    • Organizer
      3rd Annual Immuno-Oncology Summit Europe
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] 網羅的なHLAリガンドーム解析による新規がん幹細胞抗原ペプチドの同定と免疫療法への応用2018

    • Author(s)
      宮本昇
    • Organizer
      第36回日本口腔腫瘍学会総会・学術大会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi